GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Invex Therapeutics IXC.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.09

-10.00%

Close of 3 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Invex Therapeutics — daily ASX:IXC

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Invex Therapeutics on TradingView ↗
Market value
A$6.8m
Last close × shares
Volume
24.6k
Shares, 3 Nov 2026

About Invex Therapeutics

Its shares trade on ASX under the ticker IXC.AX. It has been listed since 5 July 2019. In the fiscal year to 30 June 2024, it reported revenue of A$1.7m and a net loss of A$1.6m. At that date it held total assets of A$6.1m and shareholders' equity of A$5.7m.

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2019-07-05. The firm is focused on developing treatments for neurological conditions and focused on developing treatments for neurological conditions. Its primary focus is Idiopathic Intracranial Hypertension (IIH), a condition of predominately overweight women of childbearing age, which can lead to disabling headaches and, in some patients, permanent vision loss. The company has completed a Phase II trial. The Company’s lead program is the development of Presendin for IIH. Presendin is a once-per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation developed by Peptron, Inc. The firm is conducting a Phase III clinical trial (IIH EVOLVE) designed to meet the requirements for market approval of Presendin for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia.

Figures and description from our data supplier, not checked against the company's own report.

More about Invex Therapeutics →

Latest on Invex Therapeutics

Our reporting

We have not reported on Invex Therapeutics yet.

Next results

18 Feb 2027

Due on 18 Feb 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Invex Therapeutics's ticker?

Invex Therapeutics trades as IXC.AX on ASX, under ISIN AU0000048621.

What was Invex Therapeutics's last closing price?

0.09 on 3 Nov 2026. The figure is in AUD and is never converted.

When does Invex Therapeutics next report results?

Results are expected on 18 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.